


# Pin-point™ cytidine base editing (CBE) platform

## Short protocol for electroporation of HEK293T cells and activated human T cells using the Lonza 4D-Nucleofector® System

### Experimental workflow:



Created with BioRender

The following is a protocol for delivering unmodified [Pin-point CBE nCas9 mRNA](#) (Cat # PNP12744, PNP12746, PNP12748), [Pin-point CBE rAPOBEC deaminase mRNA](#) (Cat # PNP12745, PNP12747, PNP12749), and Pin-point CBE sgRNAs ([validated controls](#) or [custom](#)) to HEK293T or activated primary human T cells using the Lonza 4D-Nucleofector System with the SF or P3 Primary Cell 96-well Nucleofector® Kit. For more details, please refer to the [Pin-point platform CBE technical manual](#). (EP = electroporation)

Day	Step	Details																											
-2	Plate cells	Seed cells at appropriate density. <b>HEK293T cells:</b> 3 x 10 <sup>6</sup> cells/10 cm dish; <b>Activated T cells:</b> 1 x 10 <sup>6</sup> cells/mL																											
	Prepare post-EP plates	Add appropriate cell culture medium to plates <b>HEK293T cells:</b> 96-well plates with 100 µL medium per well; <b>Activated T cells:</b> 24-well plates with 500 µL medium per well. Incubate at 37°C and 5% CO <sub>2</sub> .																											
	Prepare Pin-point base editing components	Prepare working stock solutions of mRNAs and sgRNAs according to the table below																											
	Prepare the cells	Harvest and count the cells. Transfer the desired number of cells for electroporation into a 15 mL conical tube. Wash with PBS, centrifuge at 200 x g for 10 minutes Resuspend cell pellet in electroporation buffer. <b>HEK293T cells:</b> 1 x 10 <sup>7</sup> cells/mL; <b>Activated T cells:</b> 5 x 10 <sup>7</sup> cells/mL.																											
0	Mix EP components	Gently mix mRNAs + sgRNAs + cells: <b>HEK293T cells:</b>																											
		<table border="1"> <thead> <tr> <th></th> <th>Pin-point component</th> <th>Working stock*</th> <th>Final amount per 20 µL EP</th> <th>Volume per 20 µL EP</th> </tr> </thead> <tbody> <tr> <td rowspan="4">mRNA and sgRNA mix</td> <td>CBE nCas9 mRNA</td> <td>2 µg/µL</td> <td>1.75 µg</td> <td>0.875 µL</td> </tr> <tr> <td>CBE rAPOBEC deaminase mRNA</td> <td>0.2 µg/µL*</td> <td>0.25 µg</td> <td>1.25 µL</td> </tr> <tr> <td>synthetic sgRNA</td> <td>200 µM</td> <td>6µM</td> <td>0.6 µL</td> </tr> <tr> <td>SF nucleofector solution</td> <td>-</td> <td>-</td> <td>to 10 µL</td> </tr> <tr> <td>Cells</td> <td>Cells in SF nucleofector solution</td> <td>-</td> <td>50,000 cells</td> <td>10 µL</td> </tr> </tbody> </table>		Pin-point component	Working stock*	Final amount per 20 µL EP	Volume per 20 µL EP	mRNA and sgRNA mix	CBE nCas9 mRNA	2 µg/µL	1.75 µg	0.875 µL	CBE rAPOBEC deaminase mRNA	0.2 µg/µL*	0.25 µg	1.25 µL	synthetic sgRNA	200 µM	6µM	0.6 µL	SF nucleofector solution	-	-	to 10 µL	Cells	Cells in SF nucleofector solution	-	50,000 cells	10 µL
			Pin-point component	Working stock*	Final amount per 20 µL EP	Volume per 20 µL EP																							
		mRNA and sgRNA mix	CBE nCas9 mRNA	2 µg/µL	1.75 µg	0.875 µL																							
CBE rAPOBEC deaminase mRNA	0.2 µg/µL*		0.25 µg	1.25 µL																									
synthetic sgRNA	200 µM		6µM	0.6 µL																									
SF nucleofector solution	-		-	to 10 µL																									
Cells	Cells in SF nucleofector solution	-	50,000 cells	10 µL																									
<table border="1"> <thead> <tr> <th></th> <th>Pin-point component</th> <th>Working stock*</th> <th>Final amount per 20 µL EP</th> <th>Volume per 20 µL EP</th> </tr> </thead> <tbody> <tr> <td rowspan="4">mRNA and sgRNA mix</td> <td>CBE nCas9 mRNA</td> <td>2 µg/µL</td> <td>1.5 µg</td> <td>0.75 µL</td> </tr> <tr> <td>CBE rAPOBEC deaminase mRNA</td> <td>1 µg/µL*</td> <td>0.6 µg</td> <td>0.6 µL</td> </tr> <tr> <td>synthetic sgRNA</td> <td>200 µM</td> <td>2 - 6µM</td> <td>0.2 µL of each sgRNA (0.6 µL total when using 3 sgRNAs)</td> </tr> <tr> <td>P3 nucleofector solution</td> <td>-</td> <td>-</td> <td>to 10 µL</td> </tr> <tr> <td>Cells</td> <td>Cells in P3 nucleofector solution</td> <td>-</td> <td>250,000 cells</td> <td>10 µL</td> </tr> </tbody> </table>		Pin-point component	Working stock*	Final amount per 20 µL EP	Volume per 20 µL EP	mRNA and sgRNA mix	CBE nCas9 mRNA	2 µg/µL	1.5 µg	0.75 µL	CBE rAPOBEC deaminase mRNA	1 µg/µL*	0.6 µg	0.6 µL	synthetic sgRNA	200 µM	2 - 6µM	0.2 µL of each sgRNA (0.6 µL total when using 3 sgRNAs)	P3 nucleofector solution	-	-	to 10 µL	Cells	Cells in P3 nucleofector solution	-	250,000 cells	10 µL		
	Pin-point component	Working stock*	Final amount per 20 µL EP	Volume per 20 µL EP																									
mRNA and sgRNA mix	CBE nCas9 mRNA	2 µg/µL	1.5 µg	0.75 µL																									
	CBE rAPOBEC deaminase mRNA	1 µg/µL*	0.6 µg	0.6 µL																									
	synthetic sgRNA	200 µM	2 - 6µM	0.2 µL of each sgRNA (0.6 µL total when using 3 sgRNAs)																									
	P3 nucleofector solution	-	-	to 10 µL																									
Cells	Cells in P3 nucleofector solution	-	250,000 cells	10 µL																									
<p>* CBE nCas9 mRNA and CBE rAPOBEC deaminase mRNA shipped at 2 µg/µL</p>																													
EP	EP	Electroporate 20 µL on Lonza 4D-Nucleofector System with appropriate program: <b>HEK293T cells:</b> CM-130; <b>Activated T cells:</b> EO-115. Add 80 µL of pre-warmed media without cytokines to the cuvette. Incubate at 37°C, 5% CO <sub>2</sub> for 15 - 30 mins. Gently transfer 100 µL of cells into prepared plates and disperse evenly by tilting/rocking. Incubate at 37°C, 5% CO <sub>2</sub> .																											
3-7	Post-EP analysis	Proceed with desired genotypic (Sanger sequencing) and/or phenotypic (flow cytometry) analyses of base editing levels.																											

If you have questions or comments, please reach out to [Scientific Support](#).

This product contains material of biological origin. Use for research purposes only. Do not use in humans or for diagnostic purposes. The purchaser assumes all risk and responsibility concerning reception, handling and storage.